Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’

Also Addresses Insulin Aspart CRL From FDA On Rival To NovoLog

 
• By Anju Ghangurde
  
accelerate
Glargine Opportunity Builds Up For Biocon • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business